Indian court lifts stay on Cipla's generic Sutent; firm slashes prices of anticancers
This article was originally published in Scrip
The Supreme Court of India has lifted a lower court stay against Cipla in a case concerning the potential launch of its cut-price generic version of Pfizer's anticancer, Sutent (sunitinib malate). The court action came on a day that also saw Cipla announce massive price cuts for three of its other generic anticancers.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.